FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog
(Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA’s Admelog as the first follow-on biologic version of Eli Lilly and Co’s fast-acting insulin, Humalog.
FILE PHOTO: French multinational pharmaceutical company SANOFI logo seen at their headquaters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo
The drug is a short-acting insulin product, generally administered just before meals, to help patients with diabetes control blood sugar levels after eating.
According to the Centers for Disease Control and Prevention, more than 30 million people in the United States have diabetes.